Department of Hepatobiliary and Liver Transplant Surgery, St. Vincent's, University Hospital , Dublin 4, Ireland.
Expert Rev Gastroenterol Hepatol. 2020 Jun;14(6):475-481. doi: 10.1080/17474124.2020.1765771. Epub 2020 May 13.
Cholangiocarcinoma (CCA) is a dismal disease with limited management options. Surgical resection remains the only established treatment however, due to its inherent predilection to invade vascular structures, only a fraction of patients with CCA meet resection criteria at diagnosis. Furthermore, R0 margins, crucial to obtain optimum survival can often prove elusive.
This review discusses the evolution of liver transplant for CCA, following its introduction in the 1990 s with less than exemplary outcomes. While transplantation is not standard of care, emerging data has suggested a crucial role in prolonging survival of those with CCA. Here we analyze the current role of orthotopic liver transplantation (OLT) in cirrhotic and non-cirrhotic patients, in the setting of both intrahepatic CCA and hilar CCA in order to establish whether this is a judicious use of a precious resource.
Liver transplant has a definite role in the treatment of CCA, as highlighted by ongoing clinical trials. A greater understanding of tumor biology coupled with results of current studies will help elucidate which patients will best benefit from OLT. While significant strides are being made to improve outcomes, this must be tempered with an understanding of the finite nature of liver grafts.
胆管癌(CCA)是一种预后较差的疾病,治疗选择有限。手术切除仍然是唯一被确立的治疗方法,然而,由于其固有侵袭血管结构的倾向,只有少数 CCA 患者在诊断时符合切除标准。此外,获得最佳生存所需的 R0 切缘往往难以达到。
本综述讨论了肝移植在胆管癌治疗中的发展,其在 20 世纪 90 年代引入后,结果并不理想。虽然肝移植不是标准治疗方法,但新出现的数据表明,它在延长胆管癌患者的生存方面起着关键作用。在这里,我们分析了原位肝移植(OLT)在肝硬化和非肝硬化患者中治疗肝内胆管癌和肝门部胆管癌的作用,以确定这是否是对宝贵资源的合理利用。
肝移植在胆管癌的治疗中有明确的作用,这一点在正在进行的临床试验中得到了强调。对肿瘤生物学的更深入了解以及目前研究的结果将有助于阐明哪些患者将从 OLT 中获益最大。虽然在提高治疗效果方面取得了重大进展,但必须要了解肝移植的资源是有限的。